Vedolizumab Under the Skin for Children With Colitis or Crohn's Disease
Tests how the body handles vedolizumab given under the skin in children with colitis.
Plain-language title generated from the registry record
Registry title: A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Key facts
- Where
- Hvidovre, DenmarkSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
Source: NCT06100289, who can take part
Where in Denmark
- Hvidovre HospitalHvidovre, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT06100289EU 2023-503188-40-00
- Record updated
- 3 August 2026
- Original description
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC).Read full original descriptionShow less
An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC).
The participants will be treated with vedolizumab for up to 34 weeks.
During the study, participants will visit their study clinic several times.
Inclusion: The participant weighs ≥10 kg at the time of screening and enrollment into the study; Participants with UC or CD diagnosed at least 1 month before screening. Participants with moderately to severely active disease defined as:; Participants with UC: a modified Mayo score of 5 to 9 (sum of Mayo endoscopic subscore, stool frequency subscore, and rectal bleeding subscore) with a Mayo endoscopic subscore of ≥2 (with the presence of mucosal friability excluding an endoscopic subscore of 1 and mandating a score of at least 2). (The results of screening endoscopy should be applied.); Participants with CD: a pediatric Crohn's disease activity index (PCDAI) >30 and a simple endoscopic score for Crohn's disease (SES-CD) >6 (or an SES-CD ≥4 if disease is confined to terminal ileum) at screening endoscopy; Participants who have failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: corticosteroids, immunomodulators (for example, azathioprine [AZA], 6-mercaptopurine [6-MP], methotrexate [MTX]), and/or tumor necrosis factor (TNF)-α antagonist therapy (for example, infliximab, adalimumab); Participants with evidence of UC extending proximal to the rectum (that is, not limited to proctitis), at a minimum; Participants with extensive colitis or pancolitis of >8 years' duration or left-sided colitis of >12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening; Participants with vaccinations that are up-to-date based on the countrywide accepted schedule of childhood vaccines.
Exclusion: Participants who have had previous exposure to approved or investigational anti-integrins, including but not limited to, natalizumab, efalizumab, etrolizumab, or abrilumab (AMG 181); or mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antagonists (ontamalimab), or rituximab; Participants who have had prior exposure to vedolizumab; The participant has received any live vaccinations within 30 days before first dose of study drug; Participants who currently require surgical intervention or are anticipated to require surgical intervention for UC or CD during this study; Participants with hypersensitivity or allergies to vedolizumab or any of its excipients; Participants with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders; Participants who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, known fixed stenosis of the intestine, short bowel syndrome, or >3 small intestine resections; Participants with clinical features suggesting monogenic very early-onset inflammatory bowel disease (IBD); Participants with active or latent tuberculosis (TB); Participants with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune subjects (that is, HBsAg negative and hepatitis B surface antibody [anti-HBs]-positive) may, however, be included; The participant has any identified congenital or acquired immunodeficiency (for example, common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation); Participants with a current diagnosis of indeterminate colitis; Participants with positive stool studies for ova and/or parasites or stool culture at screening visit; Participants with positive Clostridioides difficile (C difficile) stool test at screening visit.